Open Payments

STEVEN D DAVELUY

Type
Physician · Allopathic & Osteopathic Physicians / Dermatology
Where
DEARBORN, MI
NPI
1467611475
Received
$350,791 in 803 records, 2019 to 2025 ($350,078 general, $713 research)
As principal investigator
$338,800 of research payments to others in 102 records
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment221$120,741
2025Research payment1$713
2024General payment186$106,215
2023General payment130$37,029
2022General payment93$27,677
2021General payment73$7,420
2020General payment33$5,509
2019General payment66$45,486

By company

CompanyRecordsAmountYears
UCB, Inc.171$138,7272020–2025
ABBVIE INC.199$112,6402019–2025
Novartis Pharmaceuticals Corporation81$40,0122019–2025
Incyte Corporation19$17,6852024–2025
GENZYME CORPORATION29$9,4412021–2025
PFIZER INC.11$8,1642019–2025
Boehringer Ingelheim Pharmaceuticals, Inc.9$5,8792022–2025
UCB SA9$4,6852023–2025
SANOFI US SERVICES INC.3$2,5982025
Takeda Pharmaceuticals U.S.A., Inc.8$1,3582025
Insmed, Inc.8$1,1822025
Regeneron Healthcare Solutions, Inc.40$1,0612019–2025
Janssen Biotech, Inc.37$1,0432020–2025
KYOWA KIRIN, INC.6$9162025
Dermavant Sciences, Inc.8$5292023–2024
Lilly USA, LLC19$4612019–2025
Boehringer Ingelheim International GmbH3$4412024
Amgen Inc.10$3812020–2025
Krystal Biotech Inc6$3512023–2025
Helsinn Therapeutics (U.S.), Inc.20$3232019–2025
SUN PHARMACEUTICAL INDUSTRIES INC.16$3012020–2025
LEO Pharma Inc.12$2462021–2025
E.R. Squibb & Sons, L.L.C.11$2342023–2024
Janssen Scientific Affairs, LLC3$1632021–2024
Biofrontera Inc.7$1592021–2025
Ortho Dermatologics, a division of Bausch Health US, LLC2$1592019
Mallinckrodt Hospital Products Inc.2$1472023
Fresenius Kabi USA, LLC6$1442023–2024
Organogenesis Inc.6$1372021–2025
Organon Llc2$1342025
Genentech USA, Inc.8$1322020–2022
Galderma Laboratories, L.P.4$1252024–2025
Merck Sharp & Dohme LLC5$1102021–2025
Salix Pharmaceuticals, a division of Bausch Health US, LLC1$1002025
Mallinckrodt Enterprises LLC1$992019
Aroa Biosurgery Incorporated1$922020
Chiesi USA, Inc.3$642024–2025
Smith+Nephew, Inc.2$502022–2025
180 Medical, Inc.2$492024
Almirall LLC2$452022–2025
Arcutis Biotherapeutics, Inc.2$372024–2025
HARTMANN USA, INC.2$342023–2024
Regeneron Pharmaceuticals, Inc.1$302025
Acera Surgical, Inc.1$222025
GlaxoSmithKline, LLC.1$172025
DERMIRA, INC.1$172019
VYNE Pharmaceuticals Inc.1$162021
DENTSPLY IH AB1$142023
Tactile Systems Technology Inc1$132021

By nature of payment

NatureRecordsAmount
Compensation for services other than consulting, including serving as faculty or as a speaker at a v76$166,975
Consulting Fee42$130,409
Travel and Lodging103$31,639
Food and Beverage575$20,828
Research payment1$713
Education6$225

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-26UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-12-22Novartis Pharmaceuticals Corporation$2,200Consulting FeeCash or cash equivalent2025
2025-12-19Novartis Pharmaceuticals Corporation$3,300Consulting FeeCash or cash equivalentCOSENTYX Drug, Dermatology2025
2025-12-19SANOFI US SERVICES INC.$41Consulting FeeCash or cash equivalentAYVAKIT Biological, Gastroenterology2025
2025-12-18KYOWA KIRIN, INC.$800Consulting FeeCash or cash equivalent2025
2025-12-18UCB, Inc.$153Travel and LodgingCash or cash equivalentBimzelx Biological, Immunology2025
2025-12-18UCB, Inc.$88Travel and LodgingCash or cash equivalentBimzelx Biological, Immunology2025
2025-12-18UCB, Inc.$64Travel and LodgingCash or cash equivalentBimzelx Biological, Immunology2025
2025-12-18UCB, Inc.$36Travel and LodgingCash or cash equivalentBimzelx Biological, Immunology2025
2025-12-16Krystal Biotech Inc$16Food and BeverageIn-kind items and servicesVYJUVEK Drug, DERMATOLOGY2025
2025-12-12UCB, Inc.$7,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-12-12LEO Pharma Inc.$22Food and BeverageIn-kind items and servicesSPEVIGO Biological, DERMATOLOGY2025
2025-12-11Incyte Corporation$4,500Consulting FeeCash or cash equivalent2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$789Travel and LodgingIn-kind items and services2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$96Travel and LodgingIn-kind items and services2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$94Travel and LodgingIn-kind items and services2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$14Food and BeverageIn-kind items and services2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$14Food and BeverageIn-kind items and services2025
2025-12-05Takeda Pharmaceuticals U.S.A., Inc.$8Food and BeverageIn-kind items and services2025
2025-12-04Takeda Pharmaceuticals U.S.A., Inc.$219Travel and LodgingIn-kind items and services2025
2025-12-04Takeda Pharmaceuticals U.S.A., Inc.$121Travel and LodgingIn-kind items and services2025
2025-12-04Regeneron Healthcare Solutions, Inc.$21Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2025
2025-12-01ABBVIE INC.$4,025Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRINVOQ Biological, IMMUNOLOGY2025
2025-12-01PFIZER INC.$13Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-11-23UCB SA$20Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-22UCB SA$668Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-22UCB SA$659Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-22UCB SA$330Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-22UCB SA$38Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-22UCB SA$34Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-22UCB SA$26Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-21SANOFI US SERVICES INC.$2,460Consulting FeeCash or cash equivalentAYVAKIT Biological, Gastroenterology2025
2025-11-21UCB SA$65Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-21SUN PHARMACEUTICAL INDUSTRIES INC.$14Food and BeverageIn-kind items and servicesLeqselvi Biological, Dermatology2025
2025-11-20UCB, Inc.$3,800Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-11-20UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-11-20UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-11-20ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSKYRIZI Biological, IMMUNOLOGY2025
2025-11-19UCB, Inc.$115Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-19UCB, Inc.$17Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-18Incyte Corporation$1,250Consulting FeeCash or cash equivalent2025
2025-11-18UCB, Inc.$667Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-18UCB, Inc.$641Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-18Novartis Pharmaceuticals Corporation$27Food and BeverageIn-kind items and servicesRhapsido Drug, Immunology2025
2025-11-13UCB, Inc.$75Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-12UCB, Inc.$83Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-11SANOFI US SERVICES INC.$96Food and BeverageIn-kind items and servicesAYVAKIT Biological, Gastroenterology2025
2025-11-11UCB, Inc.$40Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-07ABBVIE INC.$764Travel and LodgingIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-11-07ABBVIE INC.$175Travel and LodgingIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-11-07ABBVIE INC.$42Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-11-06UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-11-06UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-11-06GENZYME CORPORATION$24Food and BeverageIn-kind items and servicesAYVAKIT Biological, Gastroenterology2025
2025-11-04Galderma Laboratories, L.P.$37Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-11-04SUN PHARMACEUTICAL INDUSTRIES INC.$22Food and BeverageIn-kind items and servicesILUMYA Biological, Dermatology2025
2025-11-02UCB, Inc.$33Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-02UCB, Inc.$25Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-11-02Incyte Corporation$17Food and BeverageCash or cash equivalent2025
2025-11-01Incyte Corporation$132Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-11-01Novartis Pharmaceuticals Corporation$36Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-11-01Galderma Laboratories, L.P.$13Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-10-31ABBVIE INC.$1,725Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentRINVOQ Biological, IMMUNOLOGY2025
2025-10-31Incyte Corporation$25Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-10-29Novartis Pharmaceuticals Corporation$3,000Consulting FeeCash or cash equivalent2025
2025-10-24Novartis Pharmaceuticals Corporation$19Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-10-24Novartis Pharmaceuticals Corporation$2Food and BeverageIn-kind items and servicesRhapsido Drug, Immunology2025
2025-10-23Merck Sharp & Dohme LLC$30Food and BeverageIn-kind items and servicesKEYTRUDA Biological, ONCOLOGY2025
2025-10-23Acera Surgical, Inc.$22Food and BeverageIn-kind items and servicesRestrata Wound Matrix Device, Wound Care2025
2025-10-16Novartis Pharmaceuticals Corporation$6Food and BeverageIn-kind items and servicesILARIS Drug, Immunology2025
2025-10-14UCB, Inc.$36Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-10-14Janssen Biotech, Inc.$33Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-10-08UCB, Inc.$42Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-10-07SUN PHARMACEUTICAL INDUSTRIES INC.$15Food and BeverageIn-kind items and servicesLeqselvi Biological, Dermatology2025
2025-10-07ABBVIE INC.$4Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-10-02Incyte Corporation$3,000Consulting FeeCash or cash equivalent2025
2025-09-29PFIZER INC.$14Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-09-24Organogenesis Inc.$34Food and BeverageIn-kind items and servicesPURAPLY WOUND MATRIX Device, WOUND CARE2025
2025-09-23Krystal Biotech Inc$8Food and BeverageIn-kind items and servicesVYJUVEK Drug, DERMATOLOGY2025
2025-09-23ABBVIE INC.$3Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-09-19Novartis Pharmaceuticals Corporation$34Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-09-18Incyte Corporation$94Food and BeverageCash or cash equivalent2025
2025-09-18Incyte Corporation$16Food and BeverageCash or cash equivalent2025
2025-09-18Incyte Corporation$10Food and BeverageCash or cash equivalent2025
2025-09-16Krystal Biotech Inc$24Food and BeverageIn-kind items and servicesVYJUVEK Drug, DERMATOLOGY2025
2025-09-13Almirall LLC$32Food and BeverageIn-kind items and servicesSeysara Drug, Dermatology2025
2025-09-10Novartis Pharmaceuticals Corporation$713Research paymentIn-kind items and servicesCOSENTYX Drug, DermatologyResearch Publication/ Writing Support2025
2025-09-10UCB, Inc.$59Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-09-06GENZYME CORPORATION$7,983Consulting FeeCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-09-06GENZYME CORPORATION$215Travel and LodgingIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-09-06GENZYME CORPORATION$200Travel and LodgingIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-09-06GENZYME CORPORATION$115Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-09-06GENZYME CORPORATION$64Travel and LodgingCash or cash equivalentDUPIXENT Biological, Immunology2025
2025-09-05LEO Pharma Inc.$22Food and BeverageIn-kind items and servicesANZUPGO Drug, DERMATOLOGY2025
2025-09-03ABBVIE INC.$26Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-09-03Helsinn Therapeutics (U.S.), Inc.$22Food and BeverageIn-kind items and servicesVALCHLOR Drug, ONCOLOGY2025
2025-09-02Incyte Corporation$6,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentOpzelura Drug, Dermatology2025
2025-08-29Novartis Pharmaceuticals Corporation$22Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-08-27Boehringer Ingelheim Pharmaceuticals, Inc.$4,210Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSPEVIGO Drug, IMMUNOLOGY2025
2025-08-26UCB, Inc.$38Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-26ABBVIE INC.$1Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-08-19UCB, Inc.$10,800Consulting FeeCash or cash equivalentBimzelx Biological, Immunology2025
2025-08-19Boehringer Ingelheim Pharmaceuticals, Inc.$1,402Consulting FeeCash or cash equivalentSPEVIGO Drug, IMMUNOLOGY2025
2025-08-19UCB, Inc.$64Travel and LodgingCash or cash equivalentBimzelx Biological, Immunology2025
2025-08-19KYOWA KIRIN, INC.$23Food and BeverageIn-kind items and servicesPOTELIGEO Drug, MONOCLONAL ANTIBODY2025
2025-08-13Arcutis Biotherapeutics, Inc.$20Food and BeverageIn-kind items and servicesZoryve Drug, Dermatology2025
2025-08-12Incyte Corporation$821Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-08-12Incyte Corporation$251Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-08-12Incyte Corporation$76Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-08-12Incyte Corporation$64Travel and LodgingCash or cash equivalentOpzelura Drug, Dermatology2025
2025-08-05Incyte Corporation$1,250Consulting FeeCash or cash equivalent2025
2025-08-05Boehringer Ingelheim Pharmaceuticals, Inc.$103Food and BeverageIn-kind items and servicesSPEVIGO Drug, IMMUNOLOGY2025
2025-08-05UCB, Inc.$33Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-02UCB, Inc.$30Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-02UCB, Inc.$26Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-02UCB, Inc.$10Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-02UCB, Inc.$9Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-02UCB, Inc.$7Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-01UCB, Inc.$398Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-01UCB, Inc.$257Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-01UCB, Inc.$211Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-01UCB, Inc.$125Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-08-01UCB, Inc.$65Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-07-22Amgen Inc.$13Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025
2025-07-20GENZYME CORPORATION$19Food and BeverageIn-kind items and services2025
2025-07-17UCB, Inc.$32Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-07-17PFIZER INC.$21Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-07-12Incyte Corporation$46Food and BeverageCash or cash equivalent2025
2025-07-11UCB, Inc.$27Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-07-10GENZYME CORPORATION$113Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-07-09Helsinn Therapeutics (U.S.), Inc.$19Food and BeverageIn-kind items and servicesVALCHLOR Drug, ONCOLOGY2025
2025-07-08Novartis Pharmaceuticals Corporation$24Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-07-08Novartis Pharmaceuticals Corporation$0Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-07-03UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-07-03UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-07-02Chiesi USA, Inc.$17Food and BeverageCash or cash equivalentFILSUVEZ Drug, DERMATOLOGY2025
2025-06-26Insmed, Inc.$581Travel and LodgingIn-kind items and services2025
2025-06-26Insmed, Inc.$237Travel and LodgingIn-kind items and services2025
2025-06-26Insmed, Inc.$115Travel and LodgingIn-kind items and services2025
2025-06-26Insmed, Inc.$74Food and BeverageIn-kind items and services2025
2025-06-26Insmed, Inc.$64Travel and LodgingIn-kind items and services2025
2025-06-26Insmed, Inc.$51Food and BeverageIn-kind items and services2025
2025-06-26Insmed, Inc.$29Food and BeverageIn-kind items and services2025
2025-06-26Insmed, Inc.$29Food and BeverageIn-kind items and services2025
2025-06-25ABBVIE INC.$2,875Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentSKYRIZI Biological, IMMUNOLOGY2025
2025-06-13Novartis Pharmaceuticals Corporation$27Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-06-11Salix Pharmaceuticals, a division of Bausch Health US, LLC$100Food and BeverageIn-kind items and servicesCabtreo Drug, Dermatology2025
2025-06-10Janssen Biotech, Inc.$21Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-06-03ABBVIE INC.$133Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-06-03Regeneron Healthcare Solutions, Inc.$23Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-05-29UCB, Inc.$119Food and BeverageIn-kind items and services2025
2025-05-29ABBVIE INC.$20Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-05-29PFIZER INC.$16Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-05-27Janssen Biotech, Inc.$19Food and BeverageIn-kind items and servicesTREMFYA Drug, Immunology2025
2025-05-25Regeneron Healthcare Solutions, Inc.$24Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2025
2025-05-23GENZYME CORPORATION$7Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-05-22KYOWA KIRIN, INC.$26Food and BeverageIn-kind items and servicesPOTELIGEO Drug, MONOCLONAL ANTIBODY2025
2025-05-15UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-05-14Boehringer Ingelheim Pharmaceuticals, Inc.$29Food and BeverageIn-kind items and servicesSPEVIGO Drug, IMMUNOLOGY2025
2025-05-13UCB, Inc.$39Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-05-13Regeneron Healthcare Solutions, Inc.$34Food and BeverageIn-kind items and servicesLIBTAYO Biological, ONCOLOGY2025
2025-05-08GENZYME CORPORATION$137Food and BeverageIn-kind items and servicesWAYRILZ Drug, Immunology2025
2025-04-29UCB, Inc.$22Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-04-18LEO Pharma Inc.$15Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2025
2025-04-17Novartis Pharmaceuticals Corporation$34Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-04-14PFIZER INC.$15Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-04-11UCB, Inc.$38Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-04-10UCB, Inc.$64Travel and LodgingIn-kind items and servicesBimzelx Biological, Immunology2025
2025-04-09Regeneron Pharmaceuticals, Inc.$30Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-04-03KYOWA KIRIN, INC.$20Food and BeverageIn-kind items and servicesPOTELIGEO Drug, MONOCLONAL ANTIBODY2025
2025-04-02UCB, Inc.$17Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-03-28LEO Pharma Inc.$20Food and BeverageIn-kind items and servicesADBRY Biological, DERMATOLOGY2025
2025-03-26Biofrontera Inc.$30Food and BeverageIn-kind items and services2025
2025-03-20Novartis Pharmaceuticals Corporation$3,000Consulting FeeCash or cash equivalent2025
2025-03-20Novartis Pharmaceuticals Corporation$21Food and BeverageIn-kind items and servicesILARIS Drug, Immunology2025
2025-03-19ABBVIE INC.$32Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-03-18Helsinn Therapeutics (U.S.), Inc.$21Food and BeverageIn-kind items and servicesVALCHLOR Drug, ONCOLOGY2025
2025-03-14GENZYME CORPORATION$29Food and BeverageIn-kind items and servicesDUPIXENT Biological, Immunology2025
2025-03-13SUN PHARMACEUTICAL INDUSTRIES INC.$28Food and BeverageIn-kind items and servicesILUMYA Biological, Dermatology2025
2025-03-10Incyte Corporation$63Food and BeverageCash or cash equivalentOPZELURA Drug, Dermatology2025
2025-03-09Novartis Pharmaceuticals Corporation$32Food and BeverageIn-kind items and services2025
2025-02-28Galderma Laboratories, L.P.$29Food and BeverageIn-kind items and servicesNEMLUVIO Drug, DERMATITIS2025
2025-02-28KYOWA KIRIN, INC.$23EducationIn-kind items and servicesPOTELIGEO Drug, MONOCLONAL ANTIBODY2025
2025-02-28KYOWA KIRIN, INC.$22Food and BeverageIn-kind items and servicesPOTELIGEO Drug, MONOCLONAL ANTIBODY2025
2025-02-26GlaxoSmithKline, LLC.$17Food and BeverageIn-kind items and servicesBENLYSTA Biological, IMMUNOLOGY2025
2025-02-25Novartis Pharmaceuticals Corporation$16Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-02-19Smith+Nephew, Inc.$33Food and BeverageIn-kind items and servicesOASIS Device, Extra Cellular Matrix2025
2025-02-18Krystal Biotech Inc$119Food and BeverageIn-kind items and servicesVYJUVEK Drug, DERMATOLOGY2025
2025-02-17PFIZER INC.$15Food and BeverageIn-kind items and servicesCIBINQO Drug, Inflammation & Immunology2025
2025-02-11UCB, Inc.$27Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-02-07ABBVIE INC.$25Food and BeverageIn-kind items and servicesSKYRIZI Biological, IMMUNOLOGY2025
2025-02-07ABBVIE INC.$20Food and BeverageIn-kind items and servicesRINVOQ Biological, IMMUNOLOGY2025
2025-02-06UCB, Inc.$6,972Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-02-04Organon Llc$17Food and BeverageIn-kind items and servicesVTAMA Drug, Dermatology2025
2025-01-30UCB, Inc.$2,075Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentBimzelx Biological, Immunology2025
2025-01-29Regeneron Healthcare Solutions, Inc.$33Food and BeverageIn-kind items and servicesDUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION2025
2025-01-28Lilly USA, LLC$22Food and BeverageIn-kind items and servicesTALTZ Drug, Immunology2025
2025-01-24UCB, Inc.$133Food and BeverageIn-kind items and servicesBimzelx Biological, Immunology2025
2025-01-23Novartis Pharmaceuticals Corporation$16Food and BeverageIn-kind items and servicesCOSENTYX Drug, Dermatology2025
2025-01-18Amgen Inc.$113Food and BeverageIn-kind items and servicesOTEZLA Drug, Inflammation2025

The latest 200 records of 803.

Research payments naming this person as principal investigator

DateCompanyPaid toAmountStudyYear
2025-11-14SANOFI US SERVICES INC.Wayne Health Obgyn$3,509A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-11-03SANOFI US SERVICES INC.Wayne Health Obgyn$1,000A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-09-24SANOFI US SERVICES INC.Wayne Health Obgyn$6,308A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-09-24SANOFI US SERVICES INC.Wayne Health Obgyn$2,525A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-09-05SANOFI US SERVICES INC.Wayne Health Obgyn$1,660A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-08-08SANOFI US SERVICES INC.Wayne Health Obgyn$1,840A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444652025
2025-08-08SANOFI US SERVICES INC.Wayne Health Obgyn$791A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444652025
2025-08-08SANOFI US SERVICES INC.Wayne Health Obgyn$1,150A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444652025
2025-08-06SANOFI US SERVICES INC.Wayne Health Obgyn$3,084A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-08-06SANOFI US SERVICES INC.Wayne Health Obgyn$165A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-08-06SANOFI US SERVICES INC.Wayne Health Obgyn$99A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-07-11SANOFI US SERVICES INC.Wayne Health Obgyn$1,150A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-07-02SANOFI US SERVICES INC.Wayne Health Obgyn$36,709A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-06-11SANOFI US SERVICES INC.Wayne Health Obgyn$224A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-06-11SANOFI US SERVICES INC.Wayne Health Obgyn$217A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-05-02SANOFI US SERVICES INC.Wayne Health Obgyn$165A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-05-02SANOFI US SERVICES INC.Wayne Health Obgyn$30,794A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-05-02SANOFI US SERVICES INC.Wayne Health Obgyn$500A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-04-02SANOFI US SERVICES INC.Wayne Health Obgyn$133A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-04-02SANOFI US SERVICES INC.Wayne Health Obgyn$277A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-03-26SANOFI US SERVICES INC.Wayne Health Obgyn$1,750A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-03-19SANOFI US SERVICES INC.Wayne Health Obgyn$99A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-03-19SANOFI US SERVICES INC.Wayne Health Obgyn$3,388A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-03-07SANOFI US SERVICES INC.Wayne Health Obgyn$1,242A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2025-01-22SANOFI US SERVICES INC.Wayne Health Obgyn$5,644A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442025
2024-12-18SANOFI US SERVICES INC.Wayne Health Obgyn$930A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-11-08SANOFI US SERVICES INC.Wayne Health Obgyn$257A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-11-01SANOFI US SERVICES INC.Wayne Health Obgyn$28,642A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-11-01SANOFI US SERVICES INC.Wayne Health Obgyn$6,500A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-11-01SANOFI US SERVICES INC.Wayne Health Obgyn$500A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-11-01SANOFI US SERVICES INC.Wayne Health Obgyn$534A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-09-20SANOFI US SERVICES INC.WAYNE STATE UNIVERSITY$6,500A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444652024
2024-09-18SANOFI US SERVICES INC.WAYNE STATE UNIVERSITY$1,008A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444652024
2024-09-11SANOFI US SERVICES INC.WAYNE STATE UNIVERSITY$1,008A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2024-08-28SANOFI US SERVICES INC.WAYNE STATE UNIVERSITY$570A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR442024
2022-11-08Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$117A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-11-08Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$367A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-11-08Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$3,536A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-09-01Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$1,500A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-08-09Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$1,500A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-08-04Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$990A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-07-26Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$594A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-07-12Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2022-02-08Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2022
2021-11-23PFIZER INC.WAYNE STATE UNIVERSITY$25,190A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF0662021
2021-10-07Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$642A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-09-07Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$3,009A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-08-06PFIZER INC.WAYNE STATE UNIVERSITY$792A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF0662021
2021-07-09PFIZER INC.WAYNE STATE UNIVERSITY$7,042A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF0662021
2021-04-01Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-04-01Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$1,500A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-04-01Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$990A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-02-09Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-02-09Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$407A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2021
2021-01-12PFIZER INC.WAYNE STATE UNIVERSITY$990A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPI2021
2020-12-15Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$990A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$300A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-15Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$1,500A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-08Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$1,000A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-12-08Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-10-17PFIZER INC.WAYNE STATE UNIVERSITY$20,605A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF0662020
2020-09-03Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$2,184A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-06-18Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-06-17PFIZER INC.WAYNE STATE UNIVERSITY$6,596A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2020
2020-04-14Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$1,000A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-03-26Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-03-12PFIZER INC.WAYNE STATE UNIVERSITY$6,880A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2020
2020-03-05Regeneron Pharmaceuticals, Inc.Karmanos Cancer Hospital$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 (PD-1), IN PATIENTS WITH ADVANCED C2020
2020-02-26PFIZER INC.WAYNE STATE UNIVERSITY$390A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2020
2020-02-26PFIZER INC.WAYNE STATE UNIVERSITY$12,117AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS2020
2020-02-25PFIZER INC.WAYNE STATE UNIVERSITY$70A PHASE 2A MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF0662020
2020-02-04PFIZER INC.WAYNE STATE UNIVERSITY$7,896AN OPENLABEL EXTENSION STUDY TO ASSESS THE LONGTERM SAFETY AND EFFICACY OF PF04965842 IN ADULT PATIENTS WITH MODERATETOS2020
2020-01-23PFIZER INC.WAYNE STATE UNIVERSITY$1,557A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2020
2019-12-19Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$106A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-12-04PFIZER INC.WAYNE STATE UNIVERSITY$5,115A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-12-02Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$4,212A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-11-23PFIZER INC.WAYNE STATE UNIVERSITY$1,431A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-11-14Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-11-05PFIZER INC.WAYNE STATE UNIVERSITY$1,431A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-10-23PFIZER INC.WAYNE STATE UNIVERSITY$16,692A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-10-04PFIZER INC.WAYNE STATE UNIVERSITY$1,890A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-10-01Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$1,000A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-10-01Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-09-17Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-07-09PFIZER INC.WAYNE STATE UNIVERSITY$42A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-07-09PFIZER INC.WAYNE STATE UNIVERSITY$756A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-07-02Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$172A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-07-02Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$172A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-07-02Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-07-02Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-06-27PFIZER INC.BEAUMONT HOSPITAL - DEARBORN$70A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED MULTICENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OFPF04965842 2019
2019-06-20Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$990A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-06-20Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$1,500A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-06-11Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$3,011A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-05-16Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$1,000A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-05-16Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$660A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-05-01Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$2,649A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019
2019-02-07Regeneron Pharmaceuticals, Inc.KARMANOS CANCER HOSPITAL$7,282A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUT2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyDearborn city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Dearborn, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Dearborn, MI
County
Wayne County, MI
State
Michigan
Population B01003107,4231,772,25910,077,761
Population, 2020 census P1109,9761,793,56110,077,331
Median age B0100233.337.940.2
Under 18 B0100128.7%23.6%21.2%
65 and over B0100113.7%16.6%18.6%
Households B1100136,695700,5914,076,369
Foreign born B0500230.3%10.3%7.2%
Median household income B19013$65,324$60,539$72,875
Median family income B19113$74,152$79,522$93,357
Per capita income B19301$30,588$34,906$40,735
Poverty rate B1700124.3%20.8%13.2%
Unemployment rate B230256.6%8.7%5.7%
Civilian labor force B2302545,028828,8385,018,449
Mean commute (minutes) B0801321.724.724.2
Bachelor's degree or higher B1500334.6%27.6%32.4%
Housing units B2500139,394801,0834,622,236
Owner-occupied B2500368.4%64.8%73.2%
Renters B2500331.6%35.2%26.8%
Median home value B25077$218,800$178,500$231,600
Median gross rent B25064$1,327$1,132$1,129
White, not Hispanic B0300287.3%47.9%72.4%
Black B030023.6%36.6%13.1%
Hispanic or Latino B030022.7%6.9%5.9%
Asian B030021.8%3.7%3.4%
American Indian and Alaska Native B030020.1%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Dearborn, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.